Enrique L. Álvarez

Hospital General Universitario Gregorio Marañón — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index795citations80works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(28), Cancer Immunotherapy and Biomarkers(23), Cancer Cells and Metastasis(19), Colorectal Cancer Surgical Treatments(12), Cancer Treatment and Pharmacology(11)

Publications80 total

Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer
JNCI Journal of the National Cancer Institute·2025
Supplementary Table S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Data from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Data from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024· 1 citedOpen Access
Supplementary Figure S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S2 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Table S4 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Methods S1 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
Supplementary Figure S3 from Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024Open Access
page 1 of 4Next →

Frequent Co-authors

Sara López‐Tarruella(17), Marı́a del Monte-Millán(17), Tatiana Massarrah(16), José Á. García-Sáenz(15), Yolanda Jerez(14), Miguel Martín(14), María Cebollero(13), Isabel Echavarría(12), Fernando Moreno(11), Oscar Bueno(9), Coralia Bueno(9), I Ocaña(8), Rafael Bañares(8), Iván Márquez‐Rodas(7), Rocío Ramos‐Medina(7), Uriel Bohn(7), G. Clemente(7), Felipe A. Calvo(7), Juan Berenguer(6), Alejandro Diego‐Nieto(6)